Teva announced the launch of Niacin Extended-Release Tablets, the generic version of AbbVie’s Niaspan. Niaspan is a nicotinic acid derivative indicated for use with diet to reduce elevated total cholesterol, LDL-C, Apo B, and triglyceride levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
Its mechanism of action may involve partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity, which may increase the rate of chylomicron triglyceride removal from plasma. Niacin decreases the rate of hepatic synthesis of VLDL and LDL, and does not appear to affect fecal excretion of fats, sterols or bile acids.
Niacin Extended-Release Tablets are available in 500mg, 700mg, and 1000mg strength tablets.
For more information call (215) 591-3000 or visit TevaUSA.com.